As of November 6, 2026, Immix Biopharma, Inc. is a publicly traded company (Nasdaq: IMMX); its largest reported holder is JANUS HENDERSON GROUP Ltd., with 14% on Schedule 13G/A of August 13, 2026, then Janus Henderson (13%). The largest insider holding is Yekaterina Chudnovsky, a director, with 3,247,326 shares (4.5% of shares outstanding), per Form 4 of May 29, 2026 (Schedule 13G/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Immix Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Immix Biopharma, Inc. a real, registered company?
- Immix Biopharma, Inc. files with the SEC under CIK 1873835 (its SEC filings).
- Its shares are listed under the ticker IMMX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Los Angeles, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Immix Biopharma, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Immix Biopharma, Inc.'s owners and officers?
Immix Biopharma, Inc.: incorporated in Delaware; business address in Los Angeles, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-05-20)
- : Executive Officer, Director (Form D, 2024-05-20)
- : Director (Form D, 2024-05-20)
- : Director (Form D, 2024-05-20)
- : Director (Form D, 2024-05-20)
- : Director (Form D, 2024-05-20)
- : Director (Form D, 2024-05-20)
- : Director (Form D, 2024-05-20)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.5% |
| Schedule 13G, 2026-08-14 | Eventide Asset Management, LLC | 5.6% |
| Schedule 13G/A, 2026-08-13 | Janus Henderson Group LTD. | 14% |
| Schedule 13G/A, 2026-06-05 | Janus Henderson Group PLC | 13% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 9.1% |
| Schedule 13G/A, 2026-05-04 | Millennium Management LLC | 3.3% |
| Schedule 13G, 2026-03-20 | Millennium Management LLC | 5.3% |
| Schedule 13G, 2026-02-17 | Saturn V Capital Management LP | 6.97% |
| Schedule 13G, 2026-02-17 | Janus Henderson Group PLC | 7.4% |
Questions about who owns Immix Biopharma, Inc.
Who owns Immix Biopharma, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Immix Biopharma, Inc.: Janus Henderson Group LTD. (14%, Schedule 13G/A, filed 2026-08-13), Janus Henderson Group PLC (13%, Schedule 13G/A, filed 2026-06-05), Saturn V Capital Management LP (6.97%, Schedule 13G, filed 2026-02-17), Eventide Asset Management, LLC (5.6%, Schedule 13G, filed 2026-08-14) and Blackrock, Inc. (5.5%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Immix Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of Immix Biopharma, Inc. on this page are Janus Henderson Group LTD. (14%), Janus Henderson Group PLC (13%) and Saturn V Capital Management LP (6.97%).
When did Janus Henderson Group LTD. buy into Immix Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group LTD. on this page is the Schedule 13G/A, filed 2026-08-13, reporting 14%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Immix Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immix Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immix Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Immix Biopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 3,247,326 shares (4.5% of shares outstanding), 6,250 held directly and 3,241,076 indirectly (Form 4, 2026-05-29).
- , the chairman and chief executive: 1,141,683 shares (1.6% of shares outstanding) (Form 4, 2025-12-10).
- , a director: 1,051,471 shares (1.5% of shares outstanding), 26,250 held directly and 1,025,221 indirectly (Form 4, 2026-05-29).
- , a director: 949,250 shares (1.3% of shares outstanding), 899,250 held directly and 50,000 indirectly (Form 4, 2026-05-29).
- , a director: 925,130 shares (1.3% of shares outstanding), 428,190 held directly and 496,940 indirectly (Form 4, 2026-05-29).
Shares outstanding: 71,539,314 as of 2026-08-03, from the company's latest SEC cover page.
How much has Immix Biopharma, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-05-20 | $0 | not stated |
Keep reading
More on Immix Biopharma, Inc. and the records around it.
Immix Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Saturn V Capital Management LP also filed stake reports on 2 other companies: Monopar Therapeutics (Aug 2026), X4 Pharmaceuticals, Inc. (Feb 2026)
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/immix-biopharma